The PMPRB is a federal body that regulates the price of drugs that are subject to patent protection in Canada. According to the report, average generic drug prices in Canada declined from 63% to 36% of their brand-name counterparts between 2010 and 2014. Prices of generic drugs remain higher in Canada than foreign markets that were studied (France, Germany, Italy, Sweden, Switzerland, the United Kingdom, United States, the Netherlands, Spain, Australia, and New Zealand) although the gap between Canadian and foreign prices decreased from 2010 to 2014.
A copy of the report can be found here.Follow our FDL updates us on Twitter: @TorysFDL
Click here to subscribe to Torys' insights and updates